Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease astrocytoma
Symptom C0041341|tuberous sclerosis
Sentences 28
PubMedID- 22408430 Likewise, everolimus was approved by fda for the treatment of progressive endocrine tumours of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease and for patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (ts) (http://www.fda.gov).
PubMedID- 25682485 Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period.
PubMedID- 24708766 The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma , progressive neuroendocrine tumors of pancreatic origin , subependymal giant cell astrocytoma associated with tuberous sclerosis , and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane .
PubMedID- 23325902 Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc).
PubMedID- 22654497 Shields et al1 reported four patients with aggressive retinal astrocytoma associated with tuberous sclerosis complex.
PubMedID- 23183057 The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex.
PubMedID- 22136276 Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 22805244 Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 23404211 It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis .
PubMedID- 23138436 Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding.
PubMedID- 23231513 Everolimus (rad001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 24105488 We review the timing and use of surgery versus pharmacotherapy for the treatment of subependymal giant cell astrocytoma in patients with tuberous sclerosis complex.
PubMedID- 22234227 Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature.
PubMedID- 25493579 Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors.
PubMedID- 23229407 Neuro-oncology: everolimus for astrocytoma in tuberous sclerosis complex.
PubMedID- 24667713 Everolimus has demonstrated substantial clinical benefit in randomized, controlled, phase iii studies leading to approval for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, renal angiomyolipoma and subependymal giant-cell astrocytoma associated with tuberous sclerosis complex, as well as advanced hormone-receptor-positive (hr(+)) and human epidermal growth factor receptor-2-negative advanced breast cancer.
PubMedID- 24319280 Objective: this study was aimed to explore parents' experience of assisting children affected by tuberous sclerosis complex (tsc) with subependymal giant-cell astrocytoma (sega) manifestation, in order to understand their caring needs and expectation of support.
PubMedID- 25143481 Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex.
PubMedID- 23567018 Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 24507694 Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
PubMedID- 24244540 Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis –.
PubMedID- 20422196 The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis.
PubMedID- 23686401 Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole.
PubMedID- 24757527 Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc).
PubMedID- 20643042 Subependymal giant cell astrocytoma in tuberous sclerosis complex.
PubMedID- 25456370 Background: in the exist-1 trial, initiated on aug 10, 2009, more than 35% of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex had at least 50% reduction in sega volume after 9.6 months of treatment with everolimus.
PubMedID- 23391693 Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations.
PubMedID- 24756805 Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer.

Page: 1